UroGen Pharma
Market Cap
US$591.0m
Last Updated
2019/11/20 00:42 UTC
Data Sources
Company Financials +
Executive Summary
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies.
Snowflake
Fundamentals
Flawless balance sheet with high growth potential.
Share Price & News
How has UroGen Pharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: URGN's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
7.7%
URGN
2.5%
US Biotechs
0.9%
US Market
1 Year Return
-43.6%
URGN
10.8%
US Biotechs
16.8%
US Market
Return vs Industry: URGN underperformed the US Biotechs industry which returned 10.8% over the past year.
Return vs Market: URGN underperformed the US Market which returned 16.8% over the past year.
Shareholder returns
| URGN | Industry | Market | |
|---|---|---|---|
| 7 Day | 7.7% | 2.5% | 0.9% |
| 30 Day | 27.0% | 11.8% | 4.5% |
| 90 Day | -11.1% | 7.6% | 6.2% |
| 1 Year | -43.6%-43.6% | 11.8%10.8% | 19.4%16.8% |
| 3 Year | n/a | 18.6%14.8% | 47.5%38.0% |
| 5 Year | n/a | 5.8%0.8% | 62.0%44.1% |
Price Volatility Vs. Market
How volatile is UroGen Pharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
Here's Why We're Not Too Worried About UroGen Pharma's (NASDAQ:URGN) Cash Burn Situation2 months ago | Simply Wall St
What Kind Of Investor Owns Most Of UroGen Pharma Ltd. (NASDAQ:URGN)?2 months ago | Simply Wall St
Does UroGen Pharma Ltd. (NASDAQ:URGN) Have A High Beta?Valuation
Is UroGen Pharma undervalued compared to its fair value and its price relative to the market?
2.8x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate URGN's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate URGN's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: URGN is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: URGN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate URGN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: URGN is good value based on its PB Ratio (2.8x) compared to the US Biotechs industry average (2.9x).
Next Steps
Future Growth
How is UroGen Pharma forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
62.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: URGN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).
Earnings vs Market: URGN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: URGN's is expected to become profitable in the next 3 years.
Revenue vs Market: URGN's revenue (68.1% per year) is forecast to grow faster than the US market (7.3% per year).
High Growth Revenue: URGN's revenue (68.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: URGN is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has UroGen Pharma performed over the past 5 years?
-57.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: URGN has high quality earnings.
Growing Profit Margin: URGN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: URGN is unprofitable, and losses have increased over the past 5 years at a rate of -57.8% per year.
Accelerating Growth: Unable to compare URGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: URGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (86.5%).
Return on Equity
High ROE: URGN has a negative Return on Equity (-42.62%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is UroGen Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: URGN's short term assets ($159.9M) exceeds its short term liabilities ($14.1M)
Long Term Liabilities: URGN's short term assets ($159.9M) exceeds its long term liabilities (1.7M)
Debt to Equity History and Analysis
Debt Level: URGN is debt free.
Reducing Debt: URGN has not had any debt for past 5 years.
Balance Sheet
Inventory Level: URGN has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if URGN's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: URGN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: URGN has sufficient cash runway for 1.821845 years if free cash flow continues to reduce at historical rates of -90.5% each year.
Next Steps
Dividend
What is UroGen Pharma's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate URGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate URGN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if URGN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if URGN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of URGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of UroGen Pharma's salary, the management and board of directors tenure and is there insider trading?
1.3yrs
Average management tenure
CEO
Liz Barrett (57yo)
0.8yrs
Tenure
Ms. Elizabeth A. Barrett, also known as Liz, has been President, Chief Executive Officer and Director of UroGen Pharma Ltd. since January 3, 2019. She served as Chief Executive Officer of Novartis Oncology ...
Management Age and Tenure
1.3yrs
Average Tenure
55yo
Average Age
Experienced Management: URGN's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Age and Tenure
2.6yrs
Average Tenure
63yo
Average Age
Experienced Board: URGN's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Insider Trading
Insider Buying: URGN insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Chief Executive Officer President |
| Shares | 1,548 |
| Max Price | US$26.00 |
| Entity | Individual |
| Role | Senior Key Executive Chief Medical Officer |
| Shares | 272 |
| Max Price | US$37.01 |
| Entity | Individual |
| Role | Senior Key Executive Chief Medical Officer |
| Shares | 949 |
| Max Price | US$37.30 |
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 25.4%.
Management Team
Ron Bentsur (53yo)
- Tenure: 0.8yrs
- Compensation: US$5.95m
Gary Titus (59yo)
Consultant
- Tenure: 1.4yrs
- Compensation: US$3.49m
Stephen Mullennix
Chief Operating Officer
- Tenure: 1.8yrs
- Compensation: US$4.31m
Mark Schoenberg (61yo)
Chief Medical Officer
- Tenure: 1.9yrs
- Compensation: US$300.00k
Peter Pfreundschuh (50yo)
CFO & Secretary
- Tenure: 1.3yrs
- Compensation: US$2.49m
Liz Barrett (57yo)
President
- Tenure: 0.8yrs
Sari Prutchi-Sagiv
Marketing Director
- Tenure: 0yrs
Gil Hakim (49yo)
Consultant
- Tenure: 1.3yrs
- Compensation: US$3.86m
Marina Konorty
SVP of Research & Development and Head of Israel Operations
- Tenure: 0yrs
Kate Bechtold
Director of Corporate Communications & Investor Relations
- Tenure: 1.8yrs
Board Members
Kate Falberg (58yo)
Independent Director
- Tenure: 2.6yrs
- Compensation: US$540.33k
Fred Cohen (63yo)
Independent Director
- Tenure: 2.5yrs
- Compensation: US$525.33k
Cindy Butitta (65yo)
Independent Director
- Tenure: 2.1yrs
- Compensation: US$540.96k
Stuart Holden (76yo)
Independent Director
- Tenure: 3.9yrs
- Compensation: US$527.83k
Arie Belldegrun (70yo)
Chairman of the Board
- Tenure: 16.9yrs
- Compensation: US$1.98m
Ran Nussbaum (46yo)
Independent Director
- Tenure: 6.5yrs
- Compensation: US$525.41k
Jack Baniel
Member of Scientific Advisory Board
- Tenure: 0yrs
Liz Barrett (57yo)
President
- Tenure: 0.8yrs
Herbert Lepor
Chairman of Scientific Advisory Board
- Tenure: 0yrs
Fred Witjes
Member of Scientific Advisory Board
- Tenure: 0yrs
Company Information
UroGen Pharma Ltd.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: UroGen Pharma Ltd.
- Ticker: URGN
- Exchange: NasdaqGM
- Founded: 2004
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$590.995m
- Shares outstanding: 20.98m
- Website: https://www.urogen.com
Number of Employees
Location
- UroGen Pharma Ltd.
- 499 Park Avenue
- New York
- New York
- 10014
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| URGN | NasdaqGM (Nasdaq Global Market) | Yes | Ordinary Shares | US | USD | May 2017 |
| UR8 | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | May 2017 |
| 0XOD | LSE (London Stock Exchange) | Yes | Ordinary Shares | GB | USD | May 2017 |
Biography
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company’s lead product candidates, UGN-101 and UGN-102 are proprietary ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/11/20 00:42 |
| End of Day Share Price | 2019/11/19 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.